Top-line results from phase 3 SIERRA trial of Iomab-B announced

press

 Stockholm, 31 October, 2022 Top-line results from phase 3 SIERRA trial of Iomab-B announced Immedica’s partner Actinium Pharmaceuteuticals Inc. has announced positive top-line results from the pivotal phase 3 SIERRA trial of Iomab-B in patients with active relapsed or refractory acute myeloid leukemia. Please read Actinium’s full press release below. Immedica contacts: Anders Edvell Chief […]

Strong growth and recruitments required more office space

press

Immedica Pharma AB, a pharmaceutical company focused on commercialization of rare and specialty diseases has recently moved its head quarter to the newly established Life City near Torsplan in Stockholm. Immedica is one of several pharmaceutical companies that are located at the new facilities on Solnavägen. According to a report from Stockholms Handelskammare1, the Life […]

Patient safety – at the core of our business

Patient safety – at the core of our business Pharmacist Arvid Cronlund is more than merited to head the Drug Safety department at Immedica Pharma. He has over 20 years of experience working with patient safety. Patient safety is paramount for Immedica, since all medical products can cause side-effects. Our challenge – minimizing the risk […]